Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KetaMORE for Treatment-Resistant OUD
NCT07369089Phase 2Not yet recruiting
- Sponsor
- University of California, San Diego
- Start
- Feb 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ketamine in opioid use disorder (OUD) (2 arms), sponsored by University of California, San Diego. Primary endpoint: Abstinence. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT07369089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07369089.